Linearis Joins Two Canadian AI Health Data Projects
Sep 16, 2026
Healthcare
LenioBio Secures EU Funding for Protein Medicine Production
Jul 23, 2025
LenioBio has been awarded €3.7 million from the EU4Health program to advance its ALiCE® protein expression system, aiming for cost-effective and rapid production of protein-based medicines.
LenioBio GmbH has been awarded €3.7 million from the EU4Health program to further develop its ALiCE® cell-free protein expression system, announced in a press release. The funding, provided by the European Health and Digital Executive Agency (HaDEA), will support the project until late 2027.
The initiative aims to enhance the ALiCE® platform for the rapid and cost-effective production of protein-based medicines, including vaccines and multispecific antibodies. Key objectives include scaling up lysate production, transitioning to continuous manufacturing, and establishing quality systems for GMP-grade production.
This project aligns with the European Union's strategic goals to improve the availability and affordability of essential medicines. By advancing innovative manufacturing processes, LenioBio seeks to provide a scalable and sustainable solution for the production of complex proteins.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 16 RapidCanvas Raises $29 Million to Expand Enterprise AI Platform Oct 16 KBRA Rated Anthropic BB+ Before $35 Billion Chip Financing Oct 16 Goodweek Raises $12 Million for AI Management Platform Oct 16 Intuit Agrees to Acquire AI Billing Startup Sequence for Reported $200 Million Oct 16 Matters Raises $5 Million to Build AI Consumer BankMore from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
The Hackett Group
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Elsevier Pledges 4,000 AI Tool Licenses for European Researchers
Oct 15, 2026
Scientific Research
Benchling Launches Science Foundries for Biotech R&D
Oct 15, 2026
Biotech
ACROBiosystems Launches ACRO AIx and Rapid Antibody Validation Service
Sep 24, 2026
Biotech
Lunit and Discovery Life Sciences Partner on AI Tissue Analysis
Oct 12, 2026
Biotech
Hansa Biopharma Partners With Cradle on AI Protein Design
Oct 01, 2026
Biotech
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.